Pantoprazole Stada Stada (Pantoprazole)

Pantoprazole Stada is a proton pump inhibitor used to manage conditions linked to excess gastric acid secretion.

• Erosive oesophagitis: promotes healing of the damaged oesophageal lining.
• Gastro‑oesophageal reflux disease (GERD): reduces reflux symptoms and prevents further oesophageal injury.
• Peptic ulcer disease: supports ulcer healing by lowering gastric acidity.
• Zollinger‑Ellison syndrome: controls acid hypersecretion associated with gastrin‑producing tumours.
• Prevention of stress‑related gastric bleeding in critically ‑ intensive care patients.

• Pantoprazole irreversibly binds to the H+/K+ ATPase enzyme (gastric proton pump) on the secretory surface of parietal cells. By blocking this final step of acid production, it markedly reduces gastric acid secretion, raising gastric pH and allowing damaged mucosa to heal and symptoms to improve.

Pantoprazole may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache
• Diarrhoea
• Nausea
• Abdominal pain
• Flatulence
• Dizziness

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis)
• Clostridioides difficile‑associated colitis
• Acute interstitial nephritis
• Hepatotoxicity
• Low magnesium levels (hypomagnesemia)
• Bone fractures with long‑term use

When using Pantoprazole Stada, clinicians should consider several safety aspects.

• Renal impairment: adjust monitoring if kidney function is reduced.
• Hepatic impairment: use with caution in patients with liver disease.
• Elderly patients: monitor for electrolyte disturbances and bone health.
• Pregnancy: category B3 – weigh benefits against potential risks.
• Concomitant use with clopidogrel: may reduce antiplatelet effect.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Pantoprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet activity may increase cardiovascular risk.
• Atazanavir: decreased absorption due to higher gastric pH.
• Ketoconazole: markedly reduced oral bioavailability.

Moderate Interactions (Monitor Closely)

• Warfarin: possible alteration of INR values.
• Digoxin: modest increase in serum concentrations.
• Methotrexate: reduced renal clearance at high doses.